Literature DB >> 19962915

Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.

Ka Kit Wong1, John M Cahill, Kirk A Frey, Anca M Avram.   

Abstract

RATIONALE AND
OBJECTIVES: Hybrid single photon-emission computed tomographic (SPECT) and computed tomographic (CT) imaging for the investigation of neuroendocrine tumors allows the fusion of functional and anatomic information in a rapid and efficient method. The aim of this study was to assess the incremental diagnostic value of (111)In pentetreotide SPECT/CT imaging compared with traditional planar and SPECT imaging with respect to lesion localization and characterization and reader confidence.
MATERIALS AND METHODS: Forty-nine patients (23 male, 26 female; mean age, 56.9 years; range, 14-88 years) who underwent (111)In pentetreotide planar, SPECT, and SPECT/CT imaging were eligible for this retrospective study, including patients with suspected or confirmed carcinoid tumors (n = 24), endocrine pancreatic tumors (n = 18), medullary thyroid cancer (n = 3), paragangliomas (n = 2), and multiple endocrine neoplasia type I (n = 2). Planar and SPECT images were reviewed by two blinded readers, followed by interpretation using additional SPECT/CT images in a subsequent session. A third reader provided consensus in cases with disagreements.
RESULTS: In 55 of 89 lesions (61.8%), (111)In pentetreotide SPECT/CT imaging improved lesion localization compared to planar and SPECT imaging; in 25 of 89 lesions (28.1%), SPECT/CT imaging changed lesion classification. In 20 of 49 patients (40.8%) for reader 1 and 14 of 49 patients (28.6%) for reader 2, (111)In pentetreotide SPECT/CT imaging provided incremental diagnostic value, which was considered likely to affect patient management in twelve of 20 and seven of 14 patients, respectively. Increased reader confidence was found in 32 of 49 patients (65.3%) for both readers with uniformly high confidence after SPECT/CT interpretation.
CONCLUSIONS: Hybrid (111)In pentetreotide SPECT/CT imaging provides incremental diagnostic value and greater reader confidence over planar and SPECT imaging. This is achieved though superior lesion localization, the identification of physiologic activity, and additional anatomic information derived from the nondiagnostic CT portion of the study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962915     DOI: 10.1016/j.acra.2009.08.015

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  14 in total

1.  99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT.

Authors:  Lilian Yuri Itaya Yamaga; Guilherme Campos Carvalho Neto; Marcelo Livorsi da Cunha; Akemi Osawa; Julio Cesar Silveira Oliveira; Ricardo Quartim Fonseca; Solange Amorim Nogueira; Jairo Wagner; Marcelo Gusmão Funari
Journal:  Radiol Med       Date:  2015-11-12       Impact factor: 3.469

Review 2.  SPECT/CT and tumour imaging.

Authors:  Gad Abikhzer; Zohar Keidar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-29       Impact factor: 9.236

3.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

4.  Non-functioning gastroenteropancreatic (GEP) tumors: a 111In-Pentetreotide SPECT/CT diagnostic study.

Authors:  Angela Spanu; Orazio Schillaci; Bastiana Piras; Diego F Calvisi; Antonio Falchi; Roberta Danieli; Susanna Nuvoli; Franca Dore; Giuseppe Madeddu
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

5.  Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.

Authors:  Aurora Sainz-Esteban; Vikas Prasad; Christiane Schuchardt; Carolin Zachert; José Manuel Carril; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-20       Impact factor: 9.236

6.  111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Valentina Ambrosini; Cumali Aktolun; Richard P Baum; Angelica Bishof-Delaloye; Silvana Del Vecchio; Lorenzo Maffioli; Luc Mortelmans; Wim Oyen; Giovanna Pepe; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07       Impact factor: 9.236

Review 7.  [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors].

Authors:  Rudolf A Werner; Frank M Bengel; Thorsten Derlin
Journal:  Radiologe       Date:  2020-05       Impact factor: 0.635

Review 8.  Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice.

Authors:  Edmond Rust; Fabrice Hubele; Ettore Marzano; Bernard Goichot; Patrick Pessaux; Jean-Emmanuel Kurtz; Alessio Imperiale
Journal:  Cancer Imaging       Date:  2012-05-21       Impact factor: 3.909

9.  Improved Benefit of SPECT/CT Compared to SPECT Alone for the Accurate Localization of Endocrine and Neuroendocrine Tumors.

Authors:  Gonca G Bural; Ashok Muthukrishnan; Matthew J Oborski; James M Mountz
Journal:  Mol Imaging Radionucl Ther       Date:  2012-12-20

10.  Radionuclide small intestine imaging.

Authors:  Jiri Dolezal; Marcela Kopacova
Journal:  Gastroenterol Res Pract       Date:  2013-05-30       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.